SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Specialty Drug Pricing and Out-of-Pocket Spending on Orally Administered Anticancer Drugs in Medicare Part D, 2010 to 2019
5 references·2 citing·31 second hop
Specialty Drug Pricing and Out-of-Pocket Spending on Orally Administered Anticancer Drugs in Medicare Part D, 2010 to 2019 (2019)Specialty Drug Pricing and Out-of-Pocket …How Much Longer Will We Put Up With $100,000 Cancer Drugs? (2017)How Much Longer Will We Put U…Pricing in the Market for Anticancer Drugs (2015)Pricing in the Market for Ant…Five Years of Cancer Drug Approvals (2015)Five Years of Cancer Drug App…Market spiral pricing of cancer drugs (2013)Market spiral pricing of canc…The Medicare Payment Advisory Commission. (1998)The Medicare Payment Advisory…Many Medicare Beneficiaries Do Not Fill High-Price Specialty Drug Prescriptions (2022)Many Medicare Beneficiaries D…Association of Medical Financial Hardship and Mortality Among Cancer Survivors in the United States (2022)Association of Medical Financ…The price of innovation: new estimates of drug development costs (2003)Pharmaceutical Research and Development: What Do We Get for All that Money? (2012)Cancer Drugs in the United States: Justum Pretium—The Just Price (2013)Current Status and Trends in Performance-Based Risk-Sharing Arrangements Between Healthcare Payers and Medical Product Manufacturers (2014)In the land of pharma: A qualitative analysis of the reputational discourse of the pharmaceutical industry (2018)Financial Toxicity Following Surgical Treatment for Breast Cancer: A Cross-sectional Pilot Study (2020)Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs (2009)The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts (2013)Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study (2015)Financial toxicity and implications for cancer care in the era of molecular and immune therapies (2018)An Arm and a Leg: The Rising Cost of Cancer Drugs and Impact on Access (2021)Mental Accounting and Consumer Choice (1985)Fairness as a Constraint on Profit Seeking: Entitlements in the Market (2000)Mental Accounting and Consumer Choice (2008)The high price of anticancer drugs: origins, implications, barriers, solutions (2017)Financial toxicity in cancer care: Prevalence, causes, consequences, and reduction strategies (2019)How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment (2021)Risks in new drug development: Approval success rates for investigational drugs (2001)The $2.6 Billion Pill — Methodologic and Policy Considerations (2015)Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies (2019)Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications (2021)Drug Repurposing of Generic Drugs: Challenges and the Potential Role for Government (2023)Association of Insurance with Cancer Care Utilization and Outcomes (2008)Financial Hardships Experienced by Cancer Survivors: A Systematic Review (2016)Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer (2016)Patient and Plan Characteristics Affecting Abandonment of Oral Oncolytic Prescriptions (2011)Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia (2013)Association of Patient Out-of-Pocket Costs With Prescription Abandonment and Delay in Fills of Novel Oral Anticancer Agents (2017)The Effects of Geography and Spatial Behavior on Health Care Utilization among the Residents of a Rural Region (2005)Long‐Term Trends in Medicare Payments in the Last Year of Life (2010)Hospital Readmissions Reduction Program (2015)
this work references cited by second hop

References

  • 1998The Medicare Payment Advisory Commission.1,171 cited
  • 2015Pricing in the Market for Anticancer Drugs452 cited
  • 2015Five Years of Cancer Drug Approvals301 cited
  • 2017How Much Longer Will We Put Up With $100,000 Cancer Drugs?104 cited
  • 2013Market spiral pricing of cancer drugs92 cited

Cited by

  • 2022Association of Medical Financial Hardship and Mortality Among Cancer Survivors in the United States89 cited
  • 2022Many Medicare Beneficiaries Do Not Fill High-Price Specialty Drug Prescriptions82 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work